...
首页> 外文期刊>Cancer investigation >PIK3CA mutations and BRCA1 expression in breast cancer: potential biomarkers for chemoresistance.
【24h】

PIK3CA mutations and BRCA1 expression in breast cancer: potential biomarkers for chemoresistance.

机译:乳腺癌中PIK3CA突变和BRCA1表达:化学抗性的潜在生物标志物。

获取原文
获取原文并翻译 | 示例

摘要

Mutations in PIK3CA and alterations of BRCA1 expression are common in breast cancer and have been correlated with altered sensitivity to taxanes in human cancer cell lines and with outcome of patients. We assessed mutations in the three hotspots of PIK3CA (E542K, E545K and H1047R) and intratumoral BRCA1 mRNA expression by quantitative RT-PCR in 61 breast cancer patients. Mutations of PIK3CA were found in 17 (27.9%) and did not correlate with BRCA1 transcript levels. Correlation with clinical and pathological features identified a significant association of mutations with older patients (P = 0.03). Higher BRCA1 mRNA expression was significantly correlated with advanced disease (P = 0.01) and ERBB2 overexpression (P = 0.02). These findings may help to identify a subgroup of patients who will likely benefit from chemotherapy regimens containing microtubule-disrupting agents.
机译:PIK3CA的突变和BRCA1表达的改变在乳腺癌中很常见,并且与人类癌细胞对紫杉烷的敏感性改变以及患者的预后相关。我们通过定量RT-PCR评估了61名乳腺癌患者中PIK3CA的三个热点(E542K,E545K和H1047R)的突变和瘤内BRCA1 mRNA的表达。 PIK3CA的突变发现17(27.9%),与BRCA1转录水平无关。与临床和病理特征的相关性表明,突变与老年患者之间存在显着关联(P = 0.03)。较高的BRCA1 mRNA表达与晚期疾病(P = 0.01)和ERBB2过表达(P = 0.02)显着相关。这些发现可能有助于确定可能从含微管干扰剂化疗方案中受益的患者亚组。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号